PCP Prophylaxis in an Infant With G6PD Deficiency?
2001年1月9日 · Hemolysis and hemolytic anemia may occur among patients with G6PD deficiency if they receive TMP/SMX or dapsone. The mechanism is apparently dose-related oxidative disruption of the red blood cell ...
FDA Safety Changes: Arixtra, Sulfonylureas, Tobramycin - Medscape
2009年10月7日 · G6PD deficiency is an X-linked recessive hereditary condition in which red blood cells break down when the body is exposed to the stress of infection or certain drugs.
What's New in the New Jaundice Guidelines? - Medscape
2023年6月26日 · Neurotoxicity risk factors include a low albumin level, isoimmune hemolytic disease, glucose-6-phosphate dehydrogenase (G6PD) deficiency, or other hemolytic conditions; sepsis; or any significant ...
Genetic Basis of Drug Metabolism - Page 3 - Medscape
G6PD deficiency is a sex-linked (chromosome X) recessive trait and a widespread polymorphism, with more than 400 known variants and affecting more than 400 million people worldwide.
Toxoplasmosis in the Fetus and Newborn - Page 7 - Medscape
Universal screening and treatment during pregnancy is the most effective method to prevent Toxoplasma gondiicongenital infection and may prove to be cost effective even in low prevalence areas.
Travel Medicine in Primary Care: The Pre-Travel Consultation
2024年11月26日 · Primaquine is contraindicated in G6PD deficiency. The prevention drugs are typically continued for 7 days after the patient returns home. ... Williams: I originally thought about ciprofloxacin as ...
New Data: The Most Promising Treatments for Long COVID
2024年11月27日 · Modafinil, a medication previously used for managing narcolepsy, has also been shown effective for the treatment of fatigue and neurocognitive deficits caused by long COVID, said Viswanathan. She ...
FDA Approves Topical Tapinarof for Atopic Dermatitis - Medscape
2024年12月16日 · In ADORING 1, the proportion of patients in the tapinarof cream, 1% treatment group who achieved a score of clear (0) or almost clear (1) and a minimum 2-grade improvement from baseline at week 8 ...
FDA Approves Ensartinib for ALK+ Advanced NSCLC - Medscape
2024年12月18日 · The US Food and Drug Administration (FDA) has approved ensartinib (Ensacove, Xcovery Holdings, Inc.) for the treatment of adults with ALK-positive locally advanced or metastatic non-small cell ...
Traditional Hand Eczema Treatments May Face Obsolescence
2024年12月18日 · In this multicenter double blind trial presented at the 2024 Fall Clinical Dermatology Conference, treatment success defined as an Investigator’s Global Assessment-Chronic Hand Eczema score of 0 ...